PureTech Health plc (ADR) share price logo

PureTech Health plc (ADR)

NASDAQ: PRTC

$17.42

+0.34

(+1.99%)

as on

Bell Icon

This instrument is not available for trading on the INDmoney app on 19 May 2026

PureTech Health plc (ADR) Stock Performance

as on May 21, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $17.35
    $17.74
    downward going graph

    0.40%

    Downside

    1.84%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $14.50
    $19.92
    downward going graph

    16.76%

    Downside

    14.35%

    Upside

    downward going graph

PureTech Health plc (ADR) share price movements today

Previous Close
$17.08
Open
$17.43
Volume
128.6K
Day's Low - High
$17.35 - $17.74
52 Week Low - High
$14.50 - $19.92

PureTech Health plc (ADR) Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

PureTech Health plc (ADR) Stock Fundamentals & Key Indicators

Check PureTech Health plc (ADR) market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

0.00%

PureTech Health plc (ADR) vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of PureTech Health plc (ADR) with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
PureTech Health plc (ADR) image
PureTech Health plc (ADR)
BUY$-NANA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.1B60.79%69.8712.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$114.6B139.12%26.835.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.9B14.22%14.8829.65%0.59%

Analyst Recommendation on PureTech Health plc (ADR) Stock

Based on 6 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 6 analysts, 83.33% of analysts recommend a 'BUY' rating for PureTech Health plc (ADR). Average target price of $46

PureTech Health plc (ADR) Share Price Target

Get share price movements and forecasts by analysts on PureTech Health plc (ADR).

What analysts predicted

62.13%UPSIDE

Target Price

$46

Current Price

$17.42

Analyzed by

6 Analysts

Target

$46.00

PureTech Health plc (ADR) target price $46, a slight upside of 62.13% compared to current price of $17.42. According to 6 analysts rating.

PureTech Health plc (ADR) Quarterly Profit & Loss

All numbers in Millions USD

Sep 2022
Mar 2023
Jun 2023
Sep 2023
Mar 2024
Jun 2024
Mar 2025
Jun 2025
Mar 2026
Total Revenue
4
9
3
0
0
0
4
1
2
Gross Profit
-29
-24
0
-21
-1
-38
42
-23
1
Operating Income
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-11
-23
-25
-20
-40
-41
95
-44
-64
Net Profit Margin
-256.32%
-256.30%
-793.81%
-22607.22%
-22606.75%
-14504.51%
2366.10%
-2409.78%
-2319.59%

PureTech Health plc (ADR) Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4
0
16
8
8
9
2
3
4
4
Gross Profit
2
-70
-61
-77
8
-100
-136
-1
1
4
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-48
30
-43
421
5
-60
-50
-65
53
-109
Net Profit Margin
-1101.15%
4749.08%
-266.65%
4847.42%
71.75%
-606.85%
-2409.33%
-1972.88%
1108.33%
-2355.42%

Global Institutional Holdings in PureTech Health plc (ADR)

Funds
Holdings
Pentwater Capital Management LP
0.29%
Millennium Management LLC
0.06%
Diadema Partners LP
0.03%
Atlantic Union Bankshares Corp
0%
Persistent Asset Partners Limited
0.01%
See all

PureTech Health plc (ADR) News & Key Events

  • img

    Today's Timeline - 03 November

    Mon, 07:37 PM

    -

    Gallop Oncology reports promising results for LYT-200 in AML trial, showing over 30% complete response rate.

    Tue, 02:41 AM

    -

    PureTech announces LYT-200 data presentation at ASH meeting, highlighting ongoing trial's clinical activity in AML.

Insights on PureTech Health plc (ADR)

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 1.85M → 2.79M (in $), with an average increase of 33.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, PureTech Health plc American Depositary Shares has experienced a drawdown of -32.0%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 15.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 4.2% return, outperforming this stock by 8.8%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, PRTC stock has moved down by -4.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 95.28M → -64.88M (in $), with an average decrease of 96.1% per quarter

About PureTech Health plc (ADR)

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
OrganisationPureTech Health plc (ADR)
E-voting on sharesClick here to vote

FAQs

What is PureTech Health plc (ADR) share price today?

PureTech Health plc (ADR) share price today is $17.42 as on at the close of the market. PureTech Health plc (ADR) share today touched a day high of $17.74 and a low of $17.35.

What is the 52 week high and 52 week low for PureTech Health plc (ADR) share?

PureTech Health plc (ADR) share touched a 52 week high of $19.92 on and a 52 week low of $14.5 on . PureTech Health plc (ADR) stock price today i.e. is closed at $17.42,which is 12.55% down from its 52 week high and 20.14% up from its 52 week low.

How to invest in PureTech Health plc (ADR) Stock (PRTC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for PureTech Health plc (ADR) on INDmoney app. Click on Buy button. You can invest as low as $1.5 in PureTech Health plc (ADR) Shares that will get you 0.0861 shares as per PureTech Health plc (ADR) share price of $17.42 per share as on May 21, 2026 at 8:45 am IST.

What is the minimum amount required to buy PureTech Health plc (ADR) Stock (PRTC) from India?

Indian investors can start investing in PureTech Health plc (ADR) (PRTC) shares with as little as ₹94.68 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.80 in PureTech Health plc (ADR) stock (as per the Rupee-Dollar exchange rate as on ). Based on PureTech Health plc (ADR) share’s latest price of $17.42 as on May 21, 2026 at 8:45 am IST, you will get 0.5741 shares of PureTech Health plc (ADR). Learn more about fractional shares .